IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2− breast cancer patients after neoadjuvant chemotherapy
The IHC4 score adds prognostic value beyond the CPS-EG score in HR+/HER2- breast cancer patients post-NAC. The COMBINE score, integrating both systems, offers superior prognostic stratification, highlighting the importance of combining clinical staging with tumor biology. Future studies with independent datasets are needed to validate these findings. This study provides valuable insights for optimizing treatment decisions in HR+/HER2- breast cancer.
Authors
- Zhenhua Huang (ORCID: https://orcid.org/0000-0001-6665-7230)
- Zongqi Wu
- S. Li
- Yaping Yang
- Yao Liu (ORCID: https://orcid.org/0000-0001-6599-4454)
- Yudong Li (ORCID: https://orcid.org/0000-0002-4770-6380)
- Haiyan He (ORCID: https://orcid.org/0000-0001-5690-4664)
- Liang Jin (ORCID: https://orcid.org/0000-0002-0968-546X)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- ShenZhen People’s Hospital (CN)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1007/s10549-025-07645-2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University